GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at NIH Artificial Pancreas Conference
Bethesda, MD – April 10, 2013 – GLYSENS INCORPORATED’S presentation entitled “Long Term, Fully-Implanted, Self-Contained Subcutaneous Glucose Sensor: Results from Clinical Evaluation and Applicability for Closed Loop Systems” was delivered today by Dr. Joseph Lucisano, the Company’s president and CEO, at the “Workshop on Innovation towards an Artificial Pancreas,” held at the National Institutes of Health (NIH). The April 9-10 workshop, co-sponsored by the NIH, the U.S. Food and Drug Administration (FDA), and the Juvenile Diabetes Research Foundation (JDRF), is bringing together over 175 scientists and clinicians from around the world to discuss the latest developments related to glucose sensors, insulin pumps, algorithms, and medications in the quest to develop an “artificial pancreas” closed-loop automatic glucose control system for people with diabetes. In this context, Dr. Lucisano discussed the GlySens implantable continuous glucose monitoring (ICGM) system, and its potential for eventual application in an artificial pancreas.
From the GlySens presentation abstract: In addition to meeting objective engineering utility specifications as dictated by particular control system requirements, components comprising a closed loop artificial pancreas system must also meet minimum user acceptability requirements to ensure widespread appeal and eventual widespread application of such systems. For the glucose monitoring element in such systems, key characteristics affecting user acceptability include human factors related to the intrusiveness of the device such as: (1) comfort and level of associated “device awareness;” (2) associated demands for maintenance of any externally attached elements; and (3) associated demands for user interaction/maintenance (including especially calibration frequency). Long term, fully-implanted, self-contained sensor approaches with radio telemetry signal transmission have the potential to deliver superior performance with respect to such human factor considerations, and we have developed a long term fully-implanted subcutaneous sensor system specifically intended to address these needs.